Nobivac Piro


vaccine against babesiosis in dogs

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Nobivac Piro has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 30/05/2013

Authorisation details

Product details
Nobivac Piro
Agency product number
Active substance
  • babesia canis, inactivated
  • babesia rossi, inactivated
International non-proprietary name (INN) or common name
vaccine against babesiosis in dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

22/05/2013 Nobivac Piro - EMEA/V/C/000084 - R/0006

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for canidae

Therapeutic indication

For active immunisation of dogs of six months of age or older against Babesia canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume.

Onset of immunity: Three weeks after the basic vaccination course.

Duration of immunity: Six months after the last (re-)vaccination.

Assessment history

How useful was this page?

Add your rating